Evidence map›Paper›PMID 40852613›Full record

ArticleFrontiers in pharmacology2025

Clinicians' experience on the effectiveness of pharmacotherapy in patients with first-episode depression: a randomized controlled trial based on pharmacogenomics.

Jie Tong, Jie Yuan, Yu Qin, Na Zhu, Tingting Zhang, Xiaochun Zhu, Yuanyuan Xu, Meilin Liu, Jie Zhang, Xirong Sun

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jie Tong *Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Jie Yuan *Clinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Yu QinClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Na ZhuClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Tingting ZhangClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Xiaochun ZhuClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Yuanyuan XuClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Meilin LiuClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Jie ZhangClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.
Xirong SunClinical Research Center for Mental Disorders, Shanghai Pudong New Area Mental Health Center, School of Medicine, Tongji University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Due to differences in drug efficacy, the risk of adverse reactions, and individual differences between patients, clinicians face significant challenges in terms of selecting drugs for the treatment of depression. However, no previous studies have compared the efficacy of antidepressant treatments between psychiatrists with different levels of experience based on pharmacogenomics approach. Methods: A total of 178 patients were recruited and randomly assigned to pharmacogenomics-guided treatment group or regular treatment control group. The control group was further divided into the senior doctor and the nonsenior doctor subgroups. All participants completed pharmacogenomic assessments at baseline. They also completed the 17-items Hamilton Depression Scale (HAM-D Results: Compared with the control group, pharmacogenomics-guided group presented significant differences in DARS and ASEC scores at 32 weeks ( Conclusion: Pharmacogenomics-guided treatment can effectively mitigate the occurrence of anhedonia and side effects in patients with first-episode depression. Higher level of clinical experience among psychiatrists can lead to significant reduction in the frequency of antidepressant drug changes, and the depressive symptoms at the endpoint are negatively correlated with the clinicians' work experience. Pharmacogenomics may reduce the influence of clinical experience on treatment outcomes in primary mental healthcare settings.

Indexed as

depressionFEDfirst-episode depressionPGxpharmacogenomicspsychiatrist

Identifiers

PMID40852613
PMCPMC12367644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.